1310418-54-2

Upstream product

• 20469-65-2 1-bromo-3,5-dimethoxybenzene 
• 106120-04-1 5-bromoresorcinol 
• 75-26-3 isopropyl bromide 

Downstream Products

• 1310418-55-3 1-iodo-3,5-bis(propan-2-yloxy)benzene 
• 1370519-85-9 1-(3,5-diisopropoxyphenyl)-1-(2,6-dimethylphenyl)prop-2-yn-1-ol 
• 1370519-95-1 1-(3,5-diisopropoxyphenyl)-1-(2,6-dimethylphenyl)-3-(trimethylsilyl)prop-2-yn-1-ol 
• 1370519-90-6 (3,5-diisopropoxyphenyl)(phenyl)methanol 
• 1370519-93-9 (2,6-difluorophenyl)(3,5-diisopropoxyphenyl)methanol 
• 1335092-56-2 1-(3,5-diisopropoxyphenyl)-1-phenylprop-2-yn-1-ol 
• 1370519-91-7 (3,5-diisopropoxyphenyl)(phenyl)methanone 
• 1370519-86-0 1-(2,6-difluorophenyl)-1-(3,5-diisopropoxyphenyl)prop-2-yn-1-ol 
• 1370519-94-0 (2,6-difluorophenyl)(3,5-diisopropoxyphenyl)methanone 
• 1310418-56-4 (1S,2R,4aS,8aS)-1-[3,5-bis(propan-2-yloxy)phenoxymethyl]-2,5,5,8a-tetramethyldecahydronaphthalen-2-ol 

Relevant academic research and scientific papers

Iron-mediated C-H coupling of arenes and unactivated terminal alkenes directed by sulfur

A sulfur-directed Fe(iii)-mediated ortho C-H coupling of arenes with unactivated terminal alkenes gives products of regioselective alkene chloroarylation. The novel mechanism involves redox-activation of the arene partner and alkene addition to the result

SHIP1 MODULATORS AND METHODS RELATED THERETO

Compounds of formula (I): [Formula should be inserted here]; where [Formula should be inserted here], n, R1, R4a, R4b, R5, R7 and R8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.

New ruthenium metathesis catalysts with chelating indenylidene ligands: Synthesis, characterization and reactivity

Six new ruthenium complexes bearing a bidentate (κ2O,C)- isopropoxy-indenylidene and PPh3 or PCy3 ligands have been synthesized and characterized by 1H, 13C NMR spectroscopy and X-ray crystallography.

SHIP1 MODULATORS AND METHODS RELATED THERETO

Compounds of structure (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. Such compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of structure (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.